Pascal Finetti

Centre National de la Recherche Scientifique — France

Medicine · Health Sciences

64h-index15.6kcitations570works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(105), Breast Cancer Treatment Studies(98), Cancer Genomics and Diagnostics(82), Gene expression and cancer classification(47), Epigenetics and DNA Methylation(42)

Publications570 total

TTLL6-mediated Polyglutamylation of PurA Maintains Colonic Crypt Integrity
2025
The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage
Science Advances·2025Open Access
The plasma nanoDSF denaturation profiles predict the presence of breast cancer
Journal of Translational Medicine·2025Open Access
Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity
Oncogene·2025Open Access
Expression of antibody–drug conjugate targets in soft tissue sarcomas
ESMO Open·2025Open Access
DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer
Molecular Therapy·2025Open Access
Multi-omic analysis of colorectal adenocarcinoma identifies a new subtype of myofibroblastic cancer-associated fibroblast expressing high level of B7-H3 and with poor prognosis value
2025Open Access
Gene expression-based rationale for investigating CDK4/6 inhibitors in primitive myelofibrosis
Leukemia·2025Open Access
Abstract P1-06-27: Role of MARCKS in regulating the tumor microenvironment in inflammatory breast cancer
Clinical Cancer Research·2025
AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization
Breast Cancer Research·2025· 4 citedOpen Access
84P Tumor microenvironment modulation in inflammatory breast cancer
ESMO Open·2025Open Access
An antisense oligonucleotide targeting the heat‐shock protein HSPB5 as an innovative therapeutic approach in pulmonary fibrosis
British Journal of Pharmacology·2025· 1 citedOpen Access
The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage
2025· 1 citedOpen Access
A benchmarking study of individual somatic variant callers and voting-based ensembles for whole-exome sequencing
Briefings in Bioinformatics·2024· 6 citedOpen Access
Deciphering Folate Receptor alphaGene Expression and mRNA Signatures in Ovarian Cancer: Implications for Precision Therapies
International Journal of Molecular Sciences·2024· 1 citedOpen Access
Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapy
Journal of Translational Medicine·2024· 1 citedOpen Access
Endometrioid ovarian carcinoma landscape: pathological and molecular characterization
Molecular Oncology·2024· 6 citedOpen Access
Abstract PO3-02-07: HER2-low status in inflammatory breast cancer (IBC) is associated with hormone receptors positivity but not with pathological response to neoadjuvant chemotherapy or overall survival
Cancer Research·2024· 1 cited
Abstract PO4-05-06: Hormone receptor-positive HER2-low metastatic breast cancer (mBC): evolution of HER2 status after CDK4/6 inhibitor treatment
Cancer Research·2024· 1 cited
Mutational landscape of inflammatory breast cancer
Journal of Translational Medicine·2024· 7 citedOpen Access
page 1 of 29Next →

Frequent Co-authors

François Bertucci(46), Daniel Birnbaum(46), Emmanuelle Charafe‐Jauffret(25), Patrice Viens(23), Christophe Ginestier(16), José Adélaı̈de(16), Jocelyne Jacquemier(16), Max Chaffanet(15), Nathalie Cervera(14), Benjamin Esterni(9), Julien Wicinski(8), Émilie Mamessier(8), Florence Monville(7), Luc Xerri(7), Olivier Cabaud(6), Gilles Houvenaeghel(5), Fabrice Sircoulomb(5), Renaud Sabatier(4), Jeannine Geneix(4), Véronique Gelsi‐Boyer(4)